Genomic Cancer Testing Market Report – Research, Industry Analysis Reports and Market Demands

Global Genomic Cancer Testing Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report

Buy now

Table of Content

1 Market Overview

2 Company Profiles

3 Market Competition, by Players

3.1 Global Genomic Cancer Testing Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
- 3.2.1 Market Share of Genomic Cancer Testing by Company Revenue
- 3.2.2 Top 3 Genomic Cancer Testing Players Market Share in 2025
- 3.2.3 Top 6 Genomic Cancer Testing Players Market Share in 2025
3.3 Genomic Cancer Testing Market: Overall Company Footprint Analysis
- 3.3.1 Genomic Cancer Testing Market: Region Footprint
- 3.3.2 Genomic Cancer Testing Market: Company Product Type Footprint
- 3.3.3 Genomic Cancer Testing Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

4.1 Global Genomic Cancer Testing Consumption Value and Market Share by Type (2021-2026)
4.2 Global Genomic Cancer Testing Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

5.1 Global Genomic Cancer Testing Consumption Value Market Share by Application (2021-2026)
5.2 Global Genomic Cancer Testing Market Forecast by Application (2027-2032)

6 North America

6.1 North America Genomic Cancer Testing Consumption Value by Type (2021-2032)
6.2 North America Genomic Cancer Testing Market Size by Application (2021-2032)
6.3 North America Genomic Cancer Testing Market Size by Country
- 6.3.1 North America Genomic Cancer Testing Consumption Value by Country (2021-2032)
- 6.3.2 United States Genomic Cancer Testing Market Size and Forecast (2021-2032)
- 6.3.3 Canada Genomic Cancer Testing Market Size and Forecast (2021-2032)
- 6.3.4 Mexico Genomic Cancer Testing Market Size and Forecast (2021-2032)

7 Europe

7.1 Europe Genomic Cancer Testing Consumption Value by Type (2021-2032)
7.2 Europe Genomic Cancer Testing Consumption Value by Application (2021-2032)
7.3 Europe Genomic Cancer Testing Market Size by Country
- 7.3.1 Europe Genomic Cancer Testing Consumption Value by Country (2021-2032)
- 7.3.2 Germany Genomic Cancer Testing Market Size and Forecast (2021-2032)
- 7.3.3 France Genomic Cancer Testing Market Size and Forecast (2021-2032)
- 7.3.4 United Kingdom Genomic Cancer Testing Market Size and Forecast (2021-2032)
- 7.3.5 Russia Genomic Cancer Testing Market Size and Forecast (2021-2032)
- 7.3.6 Italy Genomic Cancer Testing Market Size and Forecast (2021-2032)

8 Asia-Pacific

8.1 Asia-Pacific Genomic Cancer Testing Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Genomic Cancer Testing Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Genomic Cancer Testing Market Size by Region
- 8.3.1 Asia-Pacific Genomic Cancer Testing Consumption Value by Region (2021-2032)
- 8.3.2 China Genomic Cancer Testing Market Size and Forecast (2021-2032)
- 8.3.3 Japan Genomic Cancer Testing Market Size and Forecast (2021-2032)
- 8.3.4 South Korea Genomic Cancer Testing Market Size and Forecast (2021-2032)
- 8.3.5 India Genomic Cancer Testing Market Size and Forecast (2021-2032)
- 8.3.6 Southeast Asia Genomic Cancer Testing Market Size and Forecast (2021-2032)
- 8.3.7 Australia Genomic Cancer Testing Market Size and Forecast (2021-2032)

9 South America

9.1 South America Genomic Cancer Testing Consumption Value by Type (2021-2032)
9.2 South America Genomic Cancer Testing Consumption Value by Application (2021-2032)
9.3 South America Genomic Cancer Testing Market Size by Country
- 9.3.1 South America Genomic Cancer Testing Consumption Value by Country (2021-2032)
- 9.3.2 Brazil Genomic Cancer Testing Market Size and Forecast (2021-2032)
- 9.3.3 Argentina Genomic Cancer Testing Market Size and Forecast (2021-2032)

10 Middle East & Africa

10.1 Middle East & Africa Genomic Cancer Testing Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Genomic Cancer Testing Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Genomic Cancer Testing Market Size by Country
- 10.3.1 Middle East & Africa Genomic Cancer Testing Consumption Value by Country (2021-2032)
- 10.3.2 Turkey Genomic Cancer Testing Market Size and Forecast (2021-2032)
- 10.3.3 Saudi Arabia Genomic Cancer Testing Market Size and Forecast (2021-2032)
- 10.3.4 UAE Genomic Cancer Testing Market Size and Forecast (2021-2032)

11 Market Dynamics

11.1 Genomic Cancer Testing Market Drivers
11.2 Genomic Cancer Testing Market Restraints
11.3 Genomic Cancer Testing Trends Analysis
11.4 Porters Five Forces Analysis
- 11.4.1 Threat of New Entrants
- 11.4.2 Bargaining Power of Suppliers
- 11.4.3 Bargaining Power of Buyers
- 11.4.4 Threat of Substitutes
- 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

12.1 Genomic Cancer Testing Industry Chain
12.2 Genomic Cancer Testing Upstream Analysis
12.3 Genomic Cancer Testing Midstream Analysis
12.4 Genomic Cancer Testing Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology
14.2 Research Process and Data Source

Description

According to our (Global Info Research) latest study, the global Genomic Cancer Testing market size was valued at US$ 17307 million in 2025 and is forecast to a readjusted size of US$ 31364 million by 2032 with a CAGR of 8.9% during review period.
Genomic Cancer Testing refers to a class of molecular diagnostic technologies and services that analyze DNA, RNA and other molecular-level genetic information in a patient's tumor tissue or body fluids (such as circulating tumor DNA, ctDNA in blood) to identify gene mutations, copy number variations, gene fusions, abnormal expression or epigenetic changes related to the occurrence, development, subtype, treatment response and recurrence of cancer.
Gross Profit Margin Levels
Genomic cancer testing is an industry with high technological barriers, high data interpretation value, but also highly dependent on laboratory automation, sample size, and payment coverage. Overall, the industry's gross profit margin is typically significantly higher than that of routine testing projects. Based on comparable listed companies and industry experience, the gross profit margin for tumor gene testing business at comprehensive laboratory companies is commonly in the 50%-60% range, while leading pure molecular diagnostics/liquid biopsy/high-end CGP companies can typically reach 60%-75%. Among these, product lines with high automation, strong data reuse capabilities, high report added value, and good medical/commercial insurance coverage usually have even higher gross profit margins. Conversely, if a company primarily focuses on customized projects, low-throughput orders, complex manual interpretation, or regional sample delivery services, the gross profit margin will be diluted by channel costs, labor costs, and logistics costs. Therefore, the core of this industry is not "how much money is made per sample tested," but rather the quality of profitability is determined by platform-based testing capabilities, database capabilities, clinical evidence capabilities, and payment capabilities. The average gross profit margin level in this industry can generally be understood as higher than traditional pathology testing, lower than pure software SaaS, but significantly higher than most routine outsourced testing projects.
Industry Drivers
The growth of the genomic cancer testing industry is primarily driven by the continued rise in the cancer burden. WHO/IARC data shows that nearly 20 million new cancer cases were diagnosed globally in 2022, and this number is projected to reach 35 million by 2050. This directly increases the long-term demand for early screening, subtyping, targeted therapy selection, efficacy evaluation, and recurrence monitoring. Secondly, the increasing penetration rate of precision medicine is the most crucial catalyst for the industry. The NCI has explicitly incorporated biomarker testing into its treatment decision-making process, and the increasing number of FDA-approved companion diagnostics means that more and more anti-tumor drugs will rely on molecular testing for patient screening. Thirdly, improvements in the payment and regulatory environment are transforming tumor gene testing from an "optional item" into "part of the standard process"—the extension of CMS's NGS coverage policy and the clear payment pricing for high-value CGP projects are strengthening the industry's business loop. Meanwhile, liquid biopsy, methylation detection, MRD, AI interpretation, and multi-omics joint analysis are continuously improving detection sensitivity, lowering sampling thresholds, and extending testing scenarios from single-diagnosis to full-course disease management. Finally, pharmaceutical companies' demand for companion diagnostics, biomarker discovery, patient stratification, and real-world evidence is also driving the industry to upgrade from a single testing business to a composite market encompassing clinical services, drug development, and data asset operation.
This report is a detailed and comprehensive analysis for global Genomic Cancer Testing market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Genomic Cancer Testing market size and forecasts, in consumption value ($ Million), 2021-2032
Global Genomic Cancer Testing market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Genomic Cancer Testing market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Genomic Cancer Testing market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Genomic Cancer Testing
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Genomic Cancer Testing market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Guardant Health (USA), Foundation Medicine (USA), Caris Life Sciences (USA), Tempus AI (USA), NeoGenomics (USA), Natera (USA), OncoDNA (Belgium), Agendia (Netherlands), Eurofins Clinical Diagnostics (Luxembourg), Unilabs Genetics (Switzerland), etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Genomic Cancer Testing market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Next-Generation Sequencing (NGS) Testing Products
Digital PCR (dPCR) Testing Products
Others
Market segment by Sample Type
Tissue Sample Testing
Blood Biopsy
Others
Market segment by Cancer Type Coverage
Broad-Spectrum Genomic Testing Products For Pan-Solid Tumors
Genome Testing Products Specifically For Single Cancer Types
Others
Market segment by Application
Healthcare Institutions
Biopharmaceuticals and Pharmaceuticals
Independent Medical Laboratories
Others
Market segment by players, this report covers
Guardant Health (USA)
Foundation Medicine (USA)
Caris Life Sciences (USA)
Tempus AI (USA)
NeoGenomics (USA)
Natera (USA)
OncoDNA (Belgium)
Agendia (Netherlands)
Eurofins Clinical Diagnostics (Luxembourg)
Unilabs Genetics (Switzerland)
Nucleix (Israel)
Genetron Health (China)
Macrogen (South Korea)
Geneseeq (China)
3DMed (China)
BGI Genomics (China)
Canhelp Genomics (China)
Lucence (Singapore)
MiRXES (Singapore)
ACT Genomics (Taiwan)
MedGenome (India)
Strand Life Sciences (India)
Sonic Genetics (Australia)
NeoGenomics (USA)
Labcorp Oncology (USA)
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Genomic Cancer Testing product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Genomic Cancer Testing, with revenue, gross margin, and global market share of Genomic Cancer Testing from 2021 to 2026.
Chapter 3, the Genomic Cancer Testing competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Genomic Cancer Testing market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Genomic Cancer Testing.
Chapter 13, to describe Genomic Cancer Testing research findings and conclusion.

Buy now